|
業務類別
|
Biotechnology |
|
業務概覽
|
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
| 公司地址
| 47 Hulfish Street, Princeton, NJ, USA, 08542 |
| 電話號碼
| +1 609 662-2000 |
| 傳真號碼
| +1 609 662-2001 |
| 公司網頁
| https://www.amicusrx.com |
| 員工數量
| 511 |
| Ms. Samantha L. Prout |
Chief Accounting Officer and Controller |
-- |
20/02/2026 |
| Mr. Jeffrey P. Castelli, PhD |
Chief Development Officer |
美元 491.81K |
20/02/2026 |
| Mr. Bradley L. Campbell |
Director, President and Chief Executive Officer |
美元 767.31K |
20/02/2026 |
| Ms. Ellen S. Rosenberg |
Chief Legal Officer, General Counsel and Corporate Secretary |
美元 514.42K |
20/02/2026 |
| Mr. David M. Clark |
Chief People Officer |
美元 482.90K |
20/02/2026 |
| Mr. Simon Nicolas Reade Harford |
Chief Financial Officer |
美元 514.42K |
20/02/2026 |
|
|
| Mr. Michael A. Kelly |
Independent Director |
20/02/2026 |
| Mr. Burke W. Whitman |
Independent Director |
20/02/2026 |
| Mr. Craig A. Wheeler |
Independent Director |
20/02/2026 |
| Ms. Margaret G. McGlynn |
Independent Director |
20/02/2026 |
| Mr. Glenn P. Sblendorio |
Independent Director |
20/02/2026 |
| Mr. Bradley L. Campbell |
Director, President and Chief Executive Officer |
20/02/2026 |
| Mr. Michael G. Raab |
Chairman of the Board |
20/02/2026 |
| Ms. Lynn Dorsey Bleil |
Independent Director |
20/02/2026 |
| Dr. Eiry W. Roberts, M.D. |
Independent Director |
20/02/2026 |
|
|
|
|
